Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
14.5M
-
Number of holders
-
98
-
Total 13F shares, excl. options
-
8.9M
-
Shares change
-
-794K
-
Total reported value, excl. options
-
$139M
-
Value change
-
-$10.8M
-
Put/Call ratio
-
0.35
-
Number of buys
-
53
-
Number of sells
-
-29
-
Price
-
$15.66
Significant Holders of Inhibrx Biosciences, Inc. - Common Stock, par value $0.0001 per share (INBX) as of Q3 2024
115 filings reported holding INBX - Inhibrx Biosciences, Inc. - Common Stock, par value $0.0001 per share as of Q3 2024.
Inhibrx Biosciences, Inc. - Common Stock, par value $0.0001 per share (INBX) has 98 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 8.9M shares
of 14.5M outstanding shares and own 61.17% of the company stock.
Largest 10 shareholders include VIKING GLOBAL INVESTORS LP (1.79M shares), PERCEPTIVE ADVISORS LLC (1.06M shares), BlackRock, Inc. (717K shares), Walleye Capital LLC (550K shares), Sofinnova Investments, Inc. (536K shares), VANGUARD GROUP INC (530K shares), Slotnik Capital, LLC (369K shares), MILLENNIUM MANAGEMENT LLC (289K shares), GEODE CAPITAL MANAGEMENT, LLC (251K shares), and MORGAN STANLEY (239K shares).
This table shows the top 98 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.